Shares of RTI Surgical Inc. (NASDAQ:RTIX) shot up 6.1% during trading on Monday . The company traded as high as $3.32 and last traded at $3.30, with a volume of 93,185 shares traded. The stock had previously closed at $3.11.

A number of research firms have recently commented on RTIX. Zacks Investment Research raised shares of RTI Surgical from a “hold” rating to a “strong-buy” rating and set a $4.75 target price for the company in a research note on Wednesday, April 20th. Craig Hallum lowered shares of RTI Surgical from a “buy” rating to a “hold” rating and lowered their price target for the stock from $6.00 to $4.00 in a research report on Thursday, July 28th.

The firm has a 50-day moving average price of $3.49 and a 200-day moving average price of $3.69. The firm has a market cap of $186.60 million and a PE ratio of 45.49.

RTI Surgical (NASDAQ:RTIX) last issued its quarterly earnings results on Wednesday, July 27th. The company reported ($0.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.03 by $0.08. The company had revenue of $67.60 million for the quarter, compared to analysts’ expectations of $66.52 million. RTI Surgical’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.04 EPS. Equities research analysts anticipate that RTI Surgical Inc. will post $0.10 EPS for the current fiscal year.

An institutional investor recently raised its position in RTI Surgical stock. Royce & Associates LLC raised its position in RTI Surgical Inc. (NASDAQ:RTIX) by 30.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,558,774 shares of the company’s stock after buying an additional 368,000 shares during the period. Royce & Associates LLC owned approximately 2.71% of RTI Surgical worth $6,188,000 at the end of the most recent quarter.

RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.